These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic? Pepin J Clin Infect Dis; 2008 May; 46(10):1493-8. PubMed ID: 18419481 [TBL] [Abstract][Full Text] [Related]
3. Best strategies in recurrent or persistent Clostridium difficile infection. Cocanour CS Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157 [TBL] [Abstract][Full Text] [Related]
4. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. Johnson S J Infect; 2009 Jun; 58(6):403-10. PubMed ID: 19394704 [TBL] [Abstract][Full Text] [Related]
5. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Johnson S Int J Antimicrob Agents; 2009 Mar; 33 Suppl 1():S33-6. PubMed ID: 19303567 [TBL] [Abstract][Full Text] [Related]
6. Past, present, and future therapies for Clostridium difficile-associated disease. Surowiec D; Kuyumjian AG; Wynd MA; Cicogna CE Ann Pharmacother; 2006 Dec; 40(12):2155-63. PubMed ID: 17148650 [TBL] [Abstract][Full Text] [Related]
7. Clostridium difficile infection in the intensive care unit. Leclair MA; Allard C; Lesur O; Pépin J J Intensive Care Med; 2010; 25(1):23-30. PubMed ID: 20034951 [TBL] [Abstract][Full Text] [Related]
8. Management of Clostridium difficile infection: thinking inside and outside the box. Gerding DN; Johnson S Clin Infect Dis; 2010 Dec; 51(11):1306-13. PubMed ID: 20979491 [TBL] [Abstract][Full Text] [Related]
9. Treatment strategies for C. difficile associated diarrhea. Stepan C; Surawicz CM Acta Gastroenterol Latinoam; 2007 Sep; 37(3):183-91. PubMed ID: 17955730 [TBL] [Abstract][Full Text] [Related]
10. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections. Lancaster JW; Matthews SJ Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993 [TBL] [Abstract][Full Text] [Related]
11. Epidemiology, diagnosis and treatment of Clostridium difficile infection. Bassetti M; Villa G; Pecori D; Arzese A; Wilcox M Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1405-23. PubMed ID: 23253319 [TBL] [Abstract][Full Text] [Related]
12. Clostridium difficile infection in older adults: a review and update on its management. Kee VR Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856 [TBL] [Abstract][Full Text] [Related]
13. [The approach to recurrent infections with Clostridium difficile]. Paz Z; Altman A Harefuah; 2008 Nov; 147(11):864-5, 942. PubMed ID: 19264004 [TBL] [Abstract][Full Text] [Related]
14. Update on Clostridium difficile-induced colitis, Part 2. Reinke CM; Messick CR Am J Hosp Pharm; 1994 Aug; 51(15):1892-901; quiz 1958-9. PubMed ID: 7942924 [TBL] [Abstract][Full Text] [Related]
15. The changing face of Clostridium difficile: what treatment options remain? Shen EP; Surawicz CM Am J Gastroenterol; 2007 Dec; 102(12):2789-92. PubMed ID: 18042108 [TBL] [Abstract][Full Text] [Related]
16. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Pépin J; Valiquette L; Gagnon S; Routhier S; Brazeau I Am J Gastroenterol; 2007 Dec; 102(12):2781-8. PubMed ID: 17900327 [TBL] [Abstract][Full Text] [Related]
17. Clinical approach to severe Clostridium difficile infection: update for the hospital practitioner. Pant C; Sferra TJ; Deshpande A; Minocha A Eur J Intern Med; 2011 Dec; 22(6):561-8. PubMed ID: 22075280 [TBL] [Abstract][Full Text] [Related]
18. [Clostridium-difficile-associated infections]. Eckert C; Barbut F Med Sci (Paris); 2010 Feb; 26(2):153-8. PubMed ID: 20188046 [TBL] [Abstract][Full Text] [Related]
19. Tigecycline for the treatment of severe Clostridium difficile infection. Larson KC; Belliveau PP; Spooner LM Ann Pharmacother; 2011 Jul; 45(7-8):1005-10. PubMed ID: 21730279 [TBL] [Abstract][Full Text] [Related]
20. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]